Buradasınız

Akut Böbrek Yetmezliğinin Non-Diyalitik Tedavisi

Nondialytic Treatment of Acute Renal Failure

Journal Name:

Publication Year:

Abstract (Original Language): 
Akut böbrek yetmezliği (ABY) hastaneye yatan tüm hastaların %5'inde, yoğun bakım ünitelerindeki hastaların ise %15-30'unda görülmektedir. Tek başına ABY'nin mortalitesi yaklaşık %10-15 iken, multi-organ disfonksiyonlarının olaya eklenmesi mortalite-yi %50-90'lara çıkarmaktadır. Hastaneye yatan hastaların büyük bir kısmında (%40-80) ABY, renal hipo-perfüzyondan kaynaklanan pre-renal tiptedir. Hasta¬ların %10-50'sinde akut böbrek yetmezliği intrarenal patolojilerden kaynaklanırken, %10'dan az bir grup¬ta ise neden post-renaldır. İntrarenal ABY'nin büyük çoğunluğu, iskemik veya nefrotoksik hasar sonucu ortaya çıkan akut tübüler nekroza (ATN) bağlıdır. Günümüzde ABY'nin önlem veya tedavisi ile ilgili verilerin büyük bir kısmı ATN ile ilgilidir (1).

REFERENCES

References: 

1. Venkataraman R, Kellum JA. Novel approaches to the treatment of acute renal failure. Expert Opin Investig Drugs 2003; 12:1353-1366.
2. Schierhout G, Roberts I. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systemic review of randomised trials. Br Med J 1998;316:961-964.
3. Kieran N, Brady HR. Clinical evaluation, management and outcome of acute renal failure. In: Johnson RJ, Feehally J (Eds), Comprehensive Clinical Nephrology, 2nd ed. London: Mosby; 2003: pp 183-206.
4. Solomon R, Werner C, Mann D, D'Elia J, Silva P. Effects of sa¬line, mannitol, and furosemide to prevent acute decreases in renal function induced by radiocontrast agents. N Engl J Med 1994;24(331):1416-1420.
5. Tepel M, van der Giet M, Schwarzfeld C, Laufer U, Liermann D, Zidek W. Prevention of radiographic-contrast-agent-indu-ced reductions in renal function by acetylcysteine. N Engl J Med 2000;343:180-184.
6. Prins JM, Buller HR, Kuijper EJ, Tange RA, Speelman P. On¬ce versus thrice daily gentamicin in patients with serious in¬fections. Lancet 1993;341:335-339.
7. Memoli B, Libetta C, Conte G, Andreucci VE. Loop diuretics and renal vasodilators in acute renal failure. Nephrol Dial Transplant 1994;9 Suppl 4:168-171.
8. Mehta RL, Pascual MT, Soroko S, Chertow GM; PICARD
Study Group. Diuretics, mortality, and nonrecovery of renal
function in acute renal failure. JAMA 2002;288:2547-2553.
9. Cantarovich F, Rangoonwala B, Lorenz H, Verho M, Esnault VL; High-Dose Flurosemide in Acute Renal Failure Study Group. High-dose furosemide for established ARF: a pros¬pective, randomized, double-blind, placebo-controlled, mul-
ticenter trial. Am J Kidney Dis 2004;44:402-409.
10. Brown CB, Ogg CS, Cameron JS. High dose frusemide in acu¬te renal failure: a controlled trial. Clin Nephrol 1981;15:90-96.
11. Lameire N, Vanholder R, Van Biesen W. Loop diuretics for patients with acute renal failure: helpful or harmful? JAMA
2002;288:2599-2601.
12. Better OS, Rubinstein I, Winaver JM, Knochel JP. Mannitol therapy revisited (1940-1997). Kidney Int 1997;52:886-894.
13. Kellum JA. Use of diuretics in the acute care setting. Kidney Int Suppl 1998;66:S67-70.
14. Gubern JM, Sancho JJ, Simo J, Sitges-Serra A. A randomized trial on the effect of mannitol on postoperative renal function in patients with obstructive jaundice. Surgery 1988;103:39-44.
15. van Valenberg PL, Hoitsma AJ, Tiggeler RG, Berden JH, van Lier HJ, Koene RA. Mannitol as an indispensable constituent
of an intraoperative hydration protocol for the prevention of acute renal failure after renal cadaveric transplantation. Transplantation 1987;44:784-788.
16. Vanholder R, Sever MS, Erek E, Lameire N. Rhabdomyolysis. J Am Soc Nephrol 2000;11:1553-1561.
17. Gunal AI, Celiker H, Dogukan A, et al. Early and vigorous fluid resuscitation prevents acute renal failure in the crush victims of catastrophic earthquakes. J Am Soc Nephrol 2004; 15:1862-1867.
18. Better OS, Rubinstein I, Reis DN. Muscle crush compartment syndrome: fulminant local edema with threatening systemic
effects. Kidney Int 2003;63:1155-1557.
19. Weisberg LS, Kurnik PB, Kurnik BR. Risk of radiocontrast nephropathy in patients with and without diabetes mellitus.
Kidney Int 1994;45:259-265.
20. Seri I, Kone BC, Gullans SR, Aperia A, Brenner BM, Baller-
mann BJ. Locally formed dopamine inhibits Na+-K+-ATPase activity in rat renal cortical tubule cells. Am J Physiol 1988;
255:F666-673.
21. Bellomo R, Chapman M, Finfer S, Hickling K, Myburgh J. Low-dose dopamine in patients with early renal dysfunction: a placebo-controlled randomised trial. Australian and New Zealand Intensive Care Society (ANZICS) Clinical Trials Group. Lancet 2000;356:2139-2143.
22. Lameire NH, De Vriese AS, Vanholder R. Prevention and nondialytic treatment of acute renal failure. Curr Opin Crit
Care 2003;9:481-490.
23. Kellum JA. The use of diuretics and dopamine in acute renal failure: a systematic review of the evidence. Crit Care 1997;
1:53-59.
24. Lepor NE. A review of contemporary prevention strategies for radiocontrast nephropathy: a focus on fenoldopam and N-acetylcysteine. Rev Cardiovasc Med 2003;4 Suppl 1:S15-20.
25. Sheinbaum R, Ignacio C, Safi HJ, Estrera A. Contemporary strategies to preserve renal function during cardiac and vas¬cular surgery. Rev Cardiovasc Med 2003;4 Suppl1:S21-28.
26. Schrier RW, Arnold PE, Van Putten VJ, Burke TJ. Cellular cal¬cium in ischemic acute renal failure: role of calcium entry blockers. Kidney Int 1987;32:313-321.
27. Epstein M. Calcium antagonists and the kidney: future therape¬utic perspectives. Am J Kidney Dis 1993;21(6 Suppl 3):16-25.
28. Neumayer HH, Junge W, Kufner A, Wenning A. Prevention of radiocontrast-media-induced nephrotoxicity by the calci¬um channel blocker nitrendipine: a prospective randomised clinical trial. Nephrol Dial Transplant 1989;4:1030-1036.
29. Russo D, Testa A, Della Volpe L, Sansone G. Randomised prospective study on renal effects of two different contrast media in humans: protective role of a calcium channel bloc-
ker. Nephron 1990;55:254-257.
30. van Riemsdijk IC, Mulder PG, de Fijter JW, et al. Addition of is-radipine (Lomir) results in a better renal function after kidney transplantation: a double-blind, randomized, placebo-control¬led, multi-center study. Transplantation 2000;70:122-126.
31. Baliga R, Ueda N, Walker PD, Shah SV. Oxidant mechanisms in toxic acute renal failure. Am J Kidney Dis 1997;29:465-477.
32. Safirstein R, Andrade L, Vieira JM. Acetylcysteine and neph-rotoxic effects of radiographic contrast agents-a new use for
an old drug. N Engl J Med 2000;343:210-212.
33. Diaz-Sandoval LJ, Kosowsky BD, Losordo DW. Acetylcyste-ine to prevent angiography-related renal tissue injury (the
APART trial). Am J Cardiol 2002;89:356-358.
Official Journal of the Turkish Society of Nephrology / Türk Nefroloji Diyaliz ve Transplantasyon Dergisi
91
0 Nondialytic Treatment of Acute Renal Failure
34. Briguori C, Manganelli F, Scarpato P, et al. Acetylcysteine and contrast agent-associated nephrotoxicity. J Am Coll Cardiol
2002;40:298-303.
35. Azmus AD, Gottschall C, Manica A, et al. Effectiveness of acetylcysteine in prevention of contrast nephropathy. J Inva¬sive Cardiol 2005;17:80-84.
36. Rahman N, Kim GE, Mathews AS, et al. Effects of atrial natri-uretic peptide in clinical acute renal failure. Kidney Int 1994; 45:1731-1738.
37. Allgren RL, Marbury TC, Rahman SN, et al. Anaritide in acu¬te tubular necrosis. N Engl J Med 1997;336:828-834.
38. Lewis J, Salem MM, Chertow GM, et al. Atrial natriuretic fac¬tor in oliguric acute renal failure. Anaritide Acute Renal Fa¬ilure Study Group. Am J Kidney Dis 2000;36:767-774.
39. Sward K, Valsson F, Odencrants P, et al. Recombinant human atrial natriuretic peptide in ischemic acute renal failure: A randomized placebo-controlled trial. Crit Care Med 2004;
32:1310-1315.
40. Kurnik BR, Allgren RL, Genter FC, Solomon RJ, Bates ER, We-
isberg LS. Prospective study of atrial natriuretic peptide for the prevention of radiocontrast-induced nephropathy. Am J
Kidney Dis 1998;31:674-680.
41. van der Zander K, Houben AJ, Hofstra L, Kroon AA, de Le-euw PW. Hemodynamic and renal effects of low-dose brain natriuretic peptide infusion in humans: a randomized, place¬bo-controlled crossover study. Am J Physiol Heart Circ Physi-
ol 2003;285:H1206-1212.
42. Arend LJ, Bakris GL, Burnett JC Jr, Megerian C, Spielman WS. Role for intrarenal adenosine in the renal hemodynamic res-
ponse to contrast media. J Lab Clin Med 1987;110:406-411.
43. Erley CM, Duda SH, Rehfuss D, et al. Prevention of radi-ocontrast-media-induced nephropathy in patients with pre¬existing renal insufficiency by hydration in combination with the adenosine antagonist theophylline. Nephrol Dial Transp¬lant 1999;14:1146-1149.
44. Kramer BK, Preuner J, Ebenburger A, et al. Lack of renopro-tective effect of theophylline during aortocoronary bypass
surgery. Nephrol Dial Transplant 2002;17:910-915.
45. Safirstein R. Gene expression in nephrotoxic and ischemic acute renal failure. J Am Soc Nephrol 1994;4:1387-1395.
46. Humes HD, Liu S. Cellular and molecular basis of renal repa¬ir in acute renal failure. J Lab Clin Med 1994;124:749-754.
47. Hammerman MR. The growth hormone-insulin-like growth factor axis in kidney re-revisited. Nephrol Dial Transplant
1999;14:1853-1860.
48. Coimbra TM, Cieslinski DA, Humes HD. Epidermal growth factor accelerates renal repair in mercuric chloride nephroto-
xicity. Am J Physiol 1990;259:F438-443.
49. Ding H, Kopple JD, Cohen A, Hirschberg R. Recombinant hu¬man insulin-like growth factor-I accelerates recovery and re¬duces catabolism in rats with ischemic acute renal failure. J
Clin Invest 1993;91:2281-2287.
50. Hirschberg R, Kopple K, Lipsett P, et al. Multicenter clinical trial of recombinant human insulin-like growth factor I in pa¬tients with acute renal failure. Kidney Int 1999; 55:2423-2432.
51. Better OS, Stein JH. Early management of shock and prophy¬laxis of acute renal failure in traumatic rhabdomyolysis. N
Engl J Med 1990; 322:825-829.

Thank you for copying data from http://www.arastirmax.com